Short answer
LIGAND PHARMACEUTICALS INC (LGND) filed an 8-K current report with the SEC on September 24, 2026 reporting Item 7.01 (Regulation FD Disclosure). Ligand entered a financing agreement with AvenCell Therapeutics for up to $47 million.
LIGAND PHARMACEUTICALS INC 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Ligand entered a financing agreement with AvenCell Therapeutics for up to $47 million
- AvenCell is developing controllable, allogeneic CAR-T therapies for cancer patients
- Transaction terms and additional information appear in Exhibit 99.1 to the 8-K
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other LIGAND PHARMACEUTICALS INC 8-K filings
Get the next LGND 8-K as it lands
Follow LGND for push alerts, or ask the research agent what this filing means.